Price to Sales: Valuing Companies Before They Turn a Profit
A fast-growing company can spend years posting losses while it captures market share, which leaves the standard P/E ratio undefined and useless for evaluating it. The price to sales (P/S) ratio solves the immediate problem by substituting revenue, a number nearly every operating company has, for earnings, but it trades one blind spot for another that investors need to understand before leaning on it.
The core principle
The price to sales ratio is calculated as P/S = market capitalization / total annual revenue, equivalently expressed per share as share price divided by revenue per share. A company valued at $3 billion with $600 million in trailing twelve month revenue carries a P/S of 3,000,000,000 / 600,000,000 = 5.0, meaning the market is paying $5 for every $1 of current annual sales. Unlike net income, which can swing to negative, get inflated by one-time gains, or be distorted by aggressive accounting choices around expense timing, revenue is a comparatively hard, verifiable number that almost every operating business reports, which is precisely why P/S became the default valuation shorthand for young, unprofitable, fast-growing companies, especially during periods when large numbers of newly public technology companies had no earnings at all to value against.
The tradeoff is that P/S says nothing about whether that revenue will ever convert into profit, and how much of each sales dollar survives as eventual earnings varies enormously by business model. A grocery chain might keep 2 to 3 cents of net margin on every dollar of revenue; a mature enterprise software company might keep 25 cents or more. Comparing their P/S ratios directly, without adjusting for that structural difference in margin potential, produces a comparison that looks rigorous and is actually meaningless. A grocery chain at a P/S of 0.3 is not automatically cheaper than a software company at a P/S of 8 once you translate both into what they might eventually earn per dollar invested.
How the math works
Example 1: computing and translating P/S into an implied margin requirement. A newly public software company has a $4 billion market cap and $250 million in trailing revenue, giving P/S = 4,000,000,000 / 250,000,000 = 16.0. To judge whether that is reasonable, translate it into an implied forward P/E by assuming a mature net margin. If the company can eventually sustain a 25% net margin, projected net income on today's revenue would be $250,000,000 x 0.25 = $62,500,000, implying a P/E of 4,000,000,000 / 62,500,000 = 64.0 on today's revenue base, before any future growth. That is a demanding number: it requires either substantial revenue growth, margin expansion beyond 25%, or both, for the current price to look reasonable within a normal multi-year holding period.
Example 2: comparing two companies with different margin structures. Retailer X has a P/S of 0.4 and a historical net margin of 3%, implying a rough forward P/E of 0.4 / 0.03 = 13.3. SaaS company Y has a P/S of 9 and a mature-stage net margin target of 22%, implying 9 / 0.22 = 40.9. On raw P/S, Retailer X looks 22 times cheaper. On margin-adjusted terms, it is roughly 3 times cheaper, a very different and far more usable conclusion, and one that still requires judgment about whether either company will actually hit its assumed margin.
How it shows up in real portfolios
P/S is the ratio investors reach for most often in the months and years after a company's IPO, when trailing earnings are negative or nonexistent and every other standard multiple is undefined. During periods of enthusiastic growth investing, it is common to see richly valued software and biotech companies trading at P/S multiples of 15, 20, or higher, prices that only make sense under aggressive assumptions about both revenue growth continuing for many years and margins eventually expanding to levels the company has never actually demonstrated, which is exactly the kind of forecast that periodically gets revised down hard when growth decelerates even modestly.
Value-tilted portfolios use low P/S screens differently, often as a first-pass filter among cyclical or out-of-favor industries such as retail, materials, or homebuilders, where revenue is stable but temporarily depressed earnings make P/E unreliable. A low P/S in these sectors can flag a company priced for a permanent decline in sales that a normal business cycle recovery would reverse, which is the more defensible use case for the ratio than chasing growth stocks on the theory that a high P/S will simply come down over time.
Consider a high-earning professional, a 38 year old anesthesiologist who allocates a modest $60,000 satellite sleeve of her portfolio to individual growth stock picks and buys shares in a fast-growing cybersecurity company at a P/S of 18, reasoning simply that "the company is growing 40% a year." Two years later, growth decelerates to 22% as the company matures and the market re-rates the stock to a P/S of 9, a halving of the multiple that erases most of the revenue growth's benefit to the share price even though the business itself never had a bad year. The lesson is not that high P/S is always wrong, it is that a high P/S already prices in years of continued strong growth, so any deceleration, even to a still-healthy rate, can produce a painful multiple contraction independent of business performance.
Analysts covering early-stage biotechnology companies face an even more extreme version of this problem, since many clinical-stage biotech firms have no meaningful product revenue at all, making even P/S undefined or based on a tiny, unrepresentative base such as early licensing income. In that specific context, investors typically abandon revenue-based multiples entirely and instead value the company against the probability-weighted worth of its drug pipeline, a reminder that P/S itself has limits and is not a universal substitute for earnings-based valuation, only a workable stopgap for companies with real, growing, if not yet profitable, revenue.
Retail sector investors encounter one more wrinkle worth naming: gross versus net revenue reporting can distort P/S comparisons between similar-looking businesses. A marketplace platform that reports the full value of goods transacted through it as revenue looks far larger, and its P/S far lower, than an economically similar competitor that reports only its own commission or take rate as revenue, even if the two businesses generate identical actual profit. Checking whether a company reports revenue gross or net of costs passed through to partners is a quiet but important step before comparing its P/S against a peer using a different accounting convention.
Actionable breakdown
- Reserve heavy reliance on P/S for unprofitable or newly public companies.
- Switch to P/E once a company has stable, positive earnings.
- Treat P/S as a stopgap, not a permanent valuation tool.
- Always compare P/S within the same industry and margin profile.
- Estimate a realistic sustainable net margin for the business.
- Divide P/S by that margin to get a comparable rough multiple.
- Check the revenue growth trend behind the current P/S.
- Decelerating growth is the single biggest risk to a high P/S.
- Watch for one-time revenue spikes that distort the base year.
- Pair P/S with gross margin as an early profitability signal.
- Rising gross margin over time supports a higher justified P/S.
- Flat or falling gross margin undermines the growth story.
Common pitfalls
P/S earns its popularity from simplicity, and that same simplicity is what lets investors reach conclusions the ratio was never built to support.
- Comparing P/S across industries with very different margin structures, producing a rigorous-looking number that is not actually comparable.
- Treating revenue growth as automatically good, when it can come from heavy discounting, debt-funded acquisitions, or unsustainable customer acquisition spending.
- Buying a low P/S stock as an obvious bargain without checking whether the low margin structure is permanent rather than cyclical.
- Ignoring that a high P/S already prices in years of future growth, so even healthy deceleration can trigger a sharp multiple contraction.
Related concepts
- Gross margin: the profitability signal that helps judge whether a company's revenue can eventually convert into strong earnings.
- P/E ratio: the earnings-based multiple to switch to once a company reaches stable profitability.
- Price to book: an asset-based alternative more relevant for financial and asset-heavy businesses.
- Growth stock: the category of company where P/S sees the heaviest use.
- Valuation ratios guide: broader context on choosing the right multiple for the business in front of you.
The bottom line
Price to sales is a useful stand-in when earnings do not yet exist, but it only becomes a fair comparison tool once you adjust it for the very different margin potential hiding behind each company's revenue.